Upload
phungthuy
View
218
Download
0
Embed Size (px)
Citation preview
The Statin Intolerant Patient
44th Refresher Course in Family Medicine Pittsburgh, Pennsylvania
March 23, 2017 Presented by Amy Haver, PharmD, BCPS
The Statin Intolerant Patient
• Review common side effects associated with statin medications
• Outline ways to manage patients with statin intolerances
• Discuss the role of non-statin therapies for management of ASCVD risk
Cardiovascular Disease (CVD) • 3 out of 10 deaths globally
• Leading cause of death in the United States
http://www.who.int/mediacentre/factsheets/fs310/en/index2.html http://www.cdc.gov/nchs/data/nvsr/nvsr65/nvsr65_02.pdf
Statins can modify CVD factors Primary prevention for patients at high risk
Secondary prevention for patients with coronary heart disease
“Statins? I can’t take statins.”
• Why?
– Side effect
– Friend or relative story
– Commercial
– Drug interaction
– Contraindication
– Cost
– Perception of benefit
Muscle aches/weakness Liver damage
Memory/cognition problems Diabetes
Cancer Headache
Difficulty sleeping Flushing of the skin
Drowsiness Dizziness
Nausea or vomiting Abdominal cramping or pain
Bloating or gas Diarrhea
Constipation Rash
Vaccine ineffectiveness
Are they intolerant to statins?
ACC. Expert Analysis. Statin Intolerance: Not a Myth. 12 Aug 2015. https://www.acc.org/latest-in-cardiology/articles/2015/08/11/09/16/statin-intolerance-not-a-myth “Atorvastatin.” Micromedex ® Solutions. Truven Health Analytics. Accessed 20 Feb 2017.
Statin Intolerance No universal definition
• American College of Cardiology (ACC) Task Force: – patients are documented to have unacceptable muscle-related
symptoms that resolve with discontinuation of therapy and occur with rechallenge on at least 2 to 3 statins, preferably ones that use different metabolic pathways and have different lipophilicity, and 1 of which is prescribed at the lowest approved dose
• NLA Statin Intolerance Task Force:
– Adverse symptoms, signs and/or laboratory abnormalities attributed by the patient and/or provider to a statin and perceived by the patient to interfere with daily life activities
• Estimated 10-20% patients are statin intolerant
Lloyd-Jones DM et al. J Am Coll Cardiol 2016;68:92-125.
National Lipid Association. 2 May 2014. www.lipid.org/util/comments/statin_release_final.pdf Banach M et al. Arch Med Sci 2015;11,1:1-23.
Adverse Effects
Let’s take a more in depth look on a few…
– Muscle related
– Memory
– New onset diabetes
Muscle Related
• Myopathy…Myalgia…Myositis…Rhabdo…
Put together…1.5-5% rate of muscle complaints
• Not always higher than placebo
• Muscle complaints often exclusion criteria
Law M et al. Am J Cardiol. 2006 Apr 17;97(8A):52C-60C. Epub 2006 Feb 3. Katz DH et al. J of Cardiovascular Pharmacology and Therapeutics 2014; 19(6):533-542.
Muscle Related Rhabdomyolysis
• Less than 0.01% incidence in patients
Myopathy • 0.1-0.2% incidence in patients (or less)
NLA Task Force. Journal of Clinical Lipidology (2014) 8, S1–S4 Kashani. Circulation. 2006;114:2788-2797.
Banach M et al. Arch Med Sci 2015; 11,1:1-23. Law M. Am J Cardiol. 2006 Apr 17;97(8A):52C-60C. Epub 2006 Feb 3.
Katz. J of Cardiovascular Pharmacology and Therapeutics 2014; 19(6):533-542. Yusuf MB et al. N Engl J Med 2016; 374:2021-31
Taylor F. Cochrane Database Syst Rev. 2013;(1)CD004816
Statin Induced Mainly occurs in first 6 month of initiation/titration Affects large muscle groups Usually bilateral and symmetrical More likely with high intensity and concomitant fibrates
1 death per 23.4 million atorvastatin prescriptions
Some data shows no difference in rates of myalgia, CK, rhabdomyolysis, or discontinuation to adverse effects
Muscle Side Effects
• Occur in general population
• Dependent on definition
• Damage is rare
• If occur, check CK and stop statin
Adverse Effects
• Muscle-related
• Memory (Cognitive Impairment)
• Diabetes
Memory (Cognitive Impairment)
• Cognitive impairment reported in case reports
• February 2012 FDA Warning
“potential for generally non-serious and
reversible cognitive side effects (memory loss,
confusion, etc.)”
http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM293705.pdf
Grouped cognitive performance scores according to domains/processes
Dementia Alzheimer Disease Mild Cognitive Impairment
• No increased risk • Possible decrease
• No increased risk • Possible decrease
• No increased risk • Possible decrease
No worsening of cognitive performance scores:
• Global cognitive performance (among cognitively intact and impaired)
• Front-executive function and working memory
• Declarative memory
• Procedural memory • Attention • Processing speed • Visuoperception • Motor Speed
Queried FDA postmarketing surveillance:
Statins: 1.9 per million prescriptions Losartan: 1.6 per million prescriptions
Clopidogrel 1.9 per million prescriptions
Richardson et al. Ann Intern Med. 2013;159:688-697.
Other studies: No evidence
• No difference in tests of cognition
– Both cognitively normal or Alzheimer’s disease
• Statin use in the elderly (>70 years old)
– No increase risk
• Dementia (moderate*)
• Alzheimer Disease (low*)
• Mild cognitive impairment (moderate*)
• Worsening global cognitive performance (moderate*)
• Deterioration of memory function (moderate*)
Ott BR et al. J Gen Intern Med. 2015; 30(3):348-58
Samaras K. Trends in Cardiovascular Medicine. 2016;(26)550-565.
High Quality Evidence is Lacking
• Need larger, higher quality studies
• Selection bias
• Deficiencies of detailed testing
• Voluntary submission
Cognitive Impairment
• Evaluate for other non-statin causes
• Stop statin and watch for reversal
• FDA warning still present
• 2013 ACC/AHA Guidelines: – Evaluate for non-statin causes
Adverse Effects
• Muscle-related
• Memory (Cognitive Impairment)
• Diabetes
New Onset Diabetes (NODM)
• Highlighted in JUPITER (rosuvastatin) - 2008 – Prevented 134 vascular events for every 54 NODM
• Contradicted WOSCOPS (pravastatin) - 1995 – Reduced NODM
N Engl J Med 1995; 333:1301-1308. Ridker PM. Lancet. 2012 Aug 11; 380(9841): 565–571.
• Meta-analysis, 1994-2009 (13 trials, n=91,140)
– Placebo-controlled and standard-care-controlled statin trials
– Patients without diabetes
1 case NODM per 255 patients on statin for 4
years 9%
5.4 events avoided per 255 patients on statin for 4
years (CTT)
Sattar N et al. Lancet 2010; 375:735-42
2.0 additional NODM cases per 1000 patient years (18.9 with high vs 16.9 with moderate)
NNTH = 498
6.5 fewer first major cardiovascular events per 1000 patient years (44.5 with high vs. 51.0 with moderate)
NNT= 155
Preiss D et al. JAMA. 2011;305(24):2556-2564
8.4% developed diabetes
20.4% experienced major cardiovascular event
NODM
• Statins associated with NODM
• Dose related effects
• Most frequently with high risk individuals
• Cardiovascular benefit exists with statins
• Risk factors for DM2 • Elderly (>70 yo)
• Women • Asian ethnicity
• Metabolic syndrome (dose effect)
Betteridge and Carmena, Nature Reviews. 2016;(12)99-110. Cederberg H et al. Diabetologia (2015) 58:1109–1117
NLA Task Force. Journal of Clinical Lipidology (2014) 8, S1–S4
Proposed mechaniams insulin sensitivity insulin secretion
Adverse Effects
• Muscle-related
• Memory (Cognitive Impairment)
• Diabetes
Adverse Effects
• Medications are not without risk
• Patient-Clinician discussion for benefits vs. risks
When they do occur….how do we manage?
The Statin Intolerant Patient
• Review common side effects associated with statin medications
• Outline ways to manage patients with statin intolerances
• Discuss the role of non-statin therapies for management of ASCVD risk
Consider Before Initiation: Baseline Monitoring
2013 ACC/AHA
2015 NLA
Lipids
• Fasting lipid panel • Measure for response • Monitor for adherence to lifestyle &
drug therapy every 3-12 months
• Baseline lipid panel • Check for response & adherence
every 4-12 months • If not at goal, intensify or send to lipid
specialist
Transaminase (ALT)
• Baseline ALT
--
Muscle Damage/Creatine Kinase (CK) Measurement
• Consider baseline CK • Check if muscle symptoms occur
--
2013 ACC/AHA Summary of Statin Initiation National Lipid Association 2015
Management of Statin Intolerance: Use Systematic Approach
Lloyd-Jones DM et al. J Am Coll Cardiol 2016;68:92-125.
Careful History (rule out other causes) Hypothyroid
Vitamin D Deficiency
Recent Exercise Interactions
Discontinue Statin
Observe Symptoms
Still there? Probably not statin
Rechallenge to verify recurrence of symptoms
Try 2-3 statins: Metabolic pathways
Lipophility Use a lower dose
Use alternative dosing
Statins Atorvastatin Fluvastatin XL Lovastatin Pitavastatin Pravastatin Rosuvastatin Simvastatin
Half-Life (Hours)
14 9 1.5 12 1.8 19 1.9
Meta-bolism
CYP3A4 CYP2C9 & CYP3A4 & CYP2C8*
CYP3A4 CYP2CP* CYP2C8*
CYP450* CYP2C9* CYP3A4
Solubility Lipophilic Lipophilic Lipophilic Lipophilic Hydrophilic Hydrophilic Lipophilic
Admin Time
Any Any Bedtime Any Any Any Bedtime
Dose/Intensity
Low Intensity
-- -- 20mg 1mg 10-20mg -- 10mg
Moderate Intensity
10-20mg 80mg 40mg 2-4mg 40-80mg 5-10mg 20-40mg
High Intensity
40-80mg -- -- -- -- 20-40mg 80mg--AVOID
*Minimal Metabolism
2013 ACC/AHA Summary of Statin Initiation ACC App for iTunes. Statin Intolerance. Accessed 20 Feb 2017.
Management of Statin Intolerance: Use Systematic Approach
Careful History (rule out other causes) Hypothyroid
Vitamin D Deficiency
Recent Exercise Interactions
Discontinue Statin
Observe Symptoms
Still there? Probably not statin
Rechallenge to verify recurrence of symptoms
Try 2-3 statins: Metabolic pathways
Lipophility Use a lower dose
Use alternative dosing
Lloyd-Jones DM et al. J Am Coll Cardiol 2016;68:92-125.
Alternative Dosing Data
• Decreased frequencymuscle recovery
• Decreased plasma concentration
• Use with longer half lives
– Rosuvastatin (t1/2=19 hours)
– Atorvastatin (t1/2=14 hours)
Keating et al. Ann Pharmacother 2013;47:398-404.
Alternate Dosing
• Decreases LDL-C
– Some studies showed no difference
~10-40% depending on frequency/dosing
• Increases tolerance
~70-90% previously intolerant patients tolerated
Every Other Day Weekly
Atorvastatin Fluvastatin
Rosuvastatin
Rosuvastatin
NLA Task Force. Journal of Clinical Lipidology (2014) 8, S1–S4 Keating et al. Ann Pharmacother 2013;47:398-404.
Strategies to Increase Tolerance
• Try another statin
• Lower dose
• Alternate Day/Weekly dosing
– start low, increase if tolerated
• What about…
– Vitamin D
– CoQ10
Vitamin D
• Not recommended in absence of low Vitamin D
– Maybe role when Vitamin D Levels are low
• Resolved myalgias when deficiencies treated suggested
• No prospective RCTs
• Statin related vs manifestation of low Vitamin D???
NLA Task Force. Journal of Clinical Lipidology (2014) 8, S1–S4 N Am J Med Sci 2015 Mar;7(3):86
Coenzyme Q10 (CoQ 10)
• Limited and conflicting evidence
• CoQ10 – mitochondrial energy production
• CoQ10 levels reduced – May parallel reduction in LDL
Statins block intermediate in
synthesis of CoQ 10
Marcoff L et al. J Am Coll Cardiol 2007;49:2231-7
CoQ 10: Meta-Analysis of RCTs
No significant
change in Plasma CK Activity
No significant effect on
muscle pain
Not recommended in guidelines
Marcoff L et al. J Am Coll Cardiol 2007;49:2231-7 ACC/AHA 2013 Guidelines
Management of Statin Intolerance: Use Systematic Approach
Careful History (rule out other causes) Hypothyroid
Vitamin D Deficiency
Recent Exercise Interactions
Discontinue Statin
Observe Symptoms
Still there? Probably not statin
Rechallenge to verify recurrence of symptoms
Try 2-3 statins: Metabolic pathways
Lipophility Use a lower dose
Use alternative dosing
Use the App!
Lloyd-Jones DM et al. J Am Coll Cardiol 2016;68:92-125.
ACC Statin Intolerance App
The Statin Intolerant Patient
• Review common side effects associated with statin medications
• Outline ways to manage patients with statin intolerances
• Discuss the role of non-statin therapies for management of ASCVD risk
2013 ACC/AHA Summary of Statin Initiation Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults
Statins only therapy included
2016 ACC Expert Consensus
• Included literature not published in 2013
• Comments on non-statin therapies
– For statin intolerant
– For patients on statins not meeting goals
Lloyd-Jones DM et al. J Am Coll Cardiol 2016;68:92-125.
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
Not previously included in 2013
ACC/AHA
Lloyd-Jones DM et al. J Am Coll Cardiol 2016;68:92-125.
Non Statin Therapies
Fenofibric acids not mentioned Niacin NOT recommended
• Double blind, randomized trial (n=18,144) – ACS within 10 days and
– LDL-C 50-100mg/dL with lipid lowering therapy or 50-125mg/dL
Ezetimibe: -Reduces absorption of
cholesterol from intestine
-Lowers LDL-C 23-24% in addition to statins
Simvastatin 40mg +Placebo
LDL-C: 69.5mg/dL*
Simvastatin 40mg + Ezetimibe 10mg LDL-C: 53.7mg/dL
Primary end point at 7 years (composite endpoint) 32.7% (with ezetimibe) vs. 34.7% (with placebo)*
*Statistically significant Cannon CP et al. N Engl J Med 2015;372:2387-97.
Non Statin Therapies
Fenofibric acids not mentioned Niacin NOT recommended
Lloyd-Jones DM et al. J Am Coll Cardiol 2016;68:92-125.
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) inhibitors
• Alirocumab (Praluent ®)
• Evolocumab (Repatha ®)
PCSK9 Protein: • Inactivates LDL receptors
PCSK9 Inhibitors • Monoclonal antibodies
• Bind to and inactivate PCSK9
• BLOCK receptor degradation
More LDL receptors to get rid of LDL-C
http://www.mayoclinic.org/-/media/kcms/gbs/patient-consumer/images/2015/11/12/16/37/kullo_fig1_ab_lg.jpgPathway pic
PCSK-9 Inhibitors • LDL-C reductions varying 26-67%
– Depending on monotherapy vs. combo with statins
– Some studies with minority patients on statins
– Familial Hypercholesteremia
• No outcome trials yet
– Cardiovascular outcomes reported have been secondary outcomes
McDonagh M et al. J Manag care Spec Pharm. 2016;22(6):641-53
Pooled data… Reduction in all-cause mortality &
Lower rates of myocardial infarction… MORE TO COME!
PCSK-9 Inhibitors: -As adjunct to diet and maximally tolerated statin therapy
-Who require additional LDL-C Lowering
Therapy Adults HeFH
HoFH Clinical CVD
Dosing (Subcutaneously)
Side Effects >5% and more common than placebo
Alirocumab x no x 75mg q 2 weeks If inadequate, 150mg q 2 weeks
• nasopharyngitis • injection site
reactions • Influenza
Evolocumab
x x* x Clinical CVD or HeFH: 140mg q2 weeks or 420mg once monthly HoFH: 420mg subQ once monthly
• nasopharyngitis, • upper respiratory
tract infection • influenza • back pain • injection site
reactions
*With other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals
Repatha® (evolocumab) Prescribing Information, Amgen
PCSK-9 Inhibitors
• Access (cardiologists/specialists/lipid clinics)
• Cost ($14,000 per year)
• Unknown outcomes (only lower LDL)
• Side effects…????
• Consensus report includes them as option
Specific algorithms for specific
patients
“Clinical ASCVD”
Not at goal… “Consider”
Lloyd-Jones DM et al. J Am Coll Cardiol 2016;68:92-125.
Future…
• Outcomes Trials
– FOURIER (Evolocumab-CVD endpoints)
– ODYSSEY Outcomes (Alirocumab-CVD endpoints)
– EBBINGHAUS (Evolocumab-Cognitive function)
• Third agent (Bococizumab®-Pfizer) discontinued
http://www.medpagetoday.com/cardiology/cardiobrief/62896
http://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor
http://www.acc.org/latest-in-cardiology/articles/2016/05/18/14/34/current-indications-cost-and-clinical-use-of-anti-pcsk9-monoclonal-antibodies?w_nav=LC
Non Statin Therapies
Fenofibric acids not mentioned Niacin NOT recommended
Lloyd-Jones DM et al. J Am Coll Cardiol 2016;68:92-125.
Other non statin therapies
• Bile acid sequestrants
• Phytosterols and soluble dietary fibers
• Lipid specialists – Mipomersen
– Lomitapide
– LDL apheresis
-Cholestyramine, Colestipol, Colesevelam
-Drug Interactions -GI side effects
-No cardiovascular outcomes
-Vegetable oil, nuts, legumes, whole grains, fruits and vegetables
-Some foods fortified with sterols
-Must be consumed with/before food
-Supplements available
http://my.clevelandclinic.org/health/articles/phytosterols-sterols-stanols-heart-health/phytosterols-diet Lloyd-Jones DM et al. J Am Coll Cardiol 2016;68:92-125.
Summary
• Many patients are intolerant to statins – Especially due to muscle complaints – Other adverse effects may occur
• Attempt to determine cause of intolerance – Use strategic approach to use statins
• Patients may benefit from non-statin therapies – Ezetimibe, PCSK-9 Inhibitors – More data is needed
The Statin Intolerant Patient
• Review common side effects associated with statin medications
• Outline ways to manage patients with statin intolerances
• Discuss the role of non-statin therapies for management of ASCVD risk